ArticleAntibiotics (Basel, Switzerland)2023
Antifungal Activity of Mycogenic Silver Nanoparticles on Clinical Yeasts and Phytopathogens.
Article in Antibiotics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 39 citations in OpenAlex.
- Mycosynthesized Silver Nanoparticles (AgNPs) for the Control of Foodborne Pathogenic Bacteria:Microorganisms · 2026Article
- Label-Free Quantitative Proteomic Analysis Reveals the Effects of Biogenic Silver Nanoparticles onACS omega · 2025Article
- Biosynthesis of silver nanoparticles by Talaromyces funiculosus for therapeutic applications and safety evaluation.Scientific reports · 2025Article
- Synergistic Activity ofInternational journal of molecular sciences · 2025Article
- Silver Nanoparticles as Antimicrobial Agents in Veterinary Medicine: Current Applications and Future Perspectives.Nanomaterials (Basel, Switzerland) · 2025Review
- AgNPs biosynthesized fromFrontiers in microbiology · 2025Article
- Antimicrobial and Antifungal Action of Biogenic Silver Nanoparticles in Combination with Antibiotics and Fungicides Against Opportunistic Bacteria and Yeast.International journal of molecular sciences · 2024Article
- Silver and Gold Compounds as Antibiotics.Antibiotics (Basel, Switzerland) · 2024Article
- Mechanism of Action of Green-Synthesized Silver Nanoparticle-Incorporated Dental Varnish Against Candida albicans.Cureus · 2024Article
- Development and characterization of three-dimensional antibacterial nanocomposite sponges of chitosan, silver nanoparticles and halloysite nanotubes.RSC advances · 2024Article
- Antibacterial Effect of Silver Nanoparticles against Oral Biofilms in Subjects with Motor and Intellectual Disabilities.Journal of functional biomaterials · 2024Article
- Comparative Study and Transcriptomic Analysis on the Antifungal Mechanism of Ag Nanoparticles and Nanowires AgainstInternational journal of nanomedicine · 2024Article
- Synergistic Antifungal Interaction betweenAntibiotics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
In this study, seven different silver nanoparticles (AgNPs) were obtained using the fungi species from the phylum Ascomycota, Aspergillus tubingensis, Aspergillus spp., Cladosporium pini-ponderosae, Fusarium proliferatum, Epicoccum nigrum, Exserohilum rostratum, and Bionectria ochroleuca, isolated from the Brazilian biodiversity, particularly from the mangrove and Caatinga biomes. The nanoparticles were coded as AgNP-AT, AgNP-Asp, AgNP-CPP, AgNP-FP, AgNP-EN, AgNP-ER, and AgNP-BO and characterized using spectrophotometry (UV-Vis), dynamic light scattering (DLS), zeta potential, transmission electron microcopy (TEM), and Fourier-transform infrared (FTIR) spectroscopy. All the AgNPs presented homogeneous size in the range from 43.4 to 120.6 nm (DLS) and from 21.8 to 35.8 nm (TEM), pH from 4.5 to 7.5, negative charge, and presence of protein coating on their surface. The antifungal activity of the AgNPs was evaluated on clinical strains of Candida albicans, and on the non-albicans species, Candida krusei, Candida glabrata, Candida parapsilosis, Candida tropicalis, and Candida guilliermondii, common in hospital infections, and against the phytopathogens Fusarium oxysporum, Fusarium phaseoli, Fusarium sacchari, Fusarium subglutinans, Fusarium verticillioides, and Curvularia lunata, which are species responsible for serious damage to agriculture production. The AgNPs were effective against the yeasts with MICs ranging from 1.25 to 40 µM and on the phytopathogens with MICs from 4 to 250 µM, indicating the promising possibility of application of these AgNPs as antifungal agents. The results indicated that the physicochemical parameters of the AgNPs, including the functional groups present on their surface, interfered with their antifungal activity. Overall, the results indicate that there is no specificity of the AgNPs for the yeasts or for the phytopathogens, which can be an advantage, increasing the possibility of application in different areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.